Phalatrikadi Kwath: Benefits, Evidence & Safety

TL;DR

Phalatrikadi Kwath is a classical Ayurvedic herbal decoction used traditionally for prameha (urinary/metabolic disorders), pandu (anemia) and kamala (jaundice): but the recipe differs across classical texts. Small human trials exist, including a 64-patient randomized trial in fatty liver disease, all testing it in combination with other medicines. (48 words. Sources: IAMJ 2021 varieties review; J-AIM 2025 NAFLD RCT, DOI 10.21760/jaims.10.11.7.)

What it is

Phalatrikadi Kwath (kwatha = decoction) is a classical Ayurvedic liquid preparation, but there is no single fixed recipe: it is a family of related formulas, and the exact composition is contested. A 2021 peer-reviewed review of its varieties traces the formulation across Charaka Samhita, Bhavaprakasha, Sharangadhara Samhita, Yogaratnakara, Vrinda Madhava, and Chakradatta, with the ingredients shifting by text and by the disease chapter (Yadav & Trivedi, IAMJ 2021):

Because the name covers several recipes, any product or study labeled "Phalatrikadi Kwath" should have its ingredient list checked individually.

Traditional use

Across the classical texts, Phalatrikadi Kwath is traditionally indicated for prameha (a group of urinary disorders discussed in modern writing alongside diabetes), pandu (anemia), kamala (jaundice), amlapitta (acid-dyspepsia), and, in the Amlapitta-chapter verse, fever and vomiting (IAMJ 2021 review; AyurmedInfo). These are traditional indications from classical literature: they are not clinical proof of efficacy against diabetes, anemia, jaundice, or any disease.

What modern research says

Several small human trials have tested Phalatrikadi Kwath, always in combination with other medicines and with small samples: so results cannot be credited to the decoction alone:

Randomized trial in fatty liver disease (strongest design). A 2025 randomized clinical trial in 64 patients with non-alcoholic fatty liver disease (J-AIM 2025;10(11), DOI 10.21760/jaims.10.11.7) compared Phalatrikadi Kwatha + Triphala Guggulu (Group A) against Phalatrikadi Kwatha + Arogyavardhana Vati (Group B) (full text). Both groups reported symptom relief; ALT/SGPT fell significantly more in Group B (37.60±14.83 vs 11.36±7.71, p<0.05), while ultrasound liver echogenicity showed no significant change. Limitations: no placebo or no-treatment arm, short follow-up, and the kwatha was only one part of a combination: the trial cannot prove Phalatrikadi Kwath itself treats fatty liver.

Open-label trial in childhood anemia. An open-label interventional trial in 30 children with pandu (anemia) given Phalatrikadi Kwatha for 30 days reported statistically significant improvements (p<0.05) in symptoms (weakness, loss of appetite) and hemoglobin percentage (J-AIM, DOI 10.21760/jaims.v5i04.937). Open-label with no control group, so placebo and time effects cannot be ruled out.

Jaundice (kamala) comparative study. A clinical study of 30 kamala patients compared Phalatrikadi Ghana Vati (500 mg) with Vasadi Ghana Vati (500 mg), each thrice daily for 15 days. Both groups improved significantly (p<0.05) on subjective and liver-function parameters, with the Phalatrikadi group improving more, and no adverse effects were noticed during the trial (IRJAY). Small, short, and unblinded.

Honest summary. Phalatrikadi Kwath has more human data than most classical decoctions, including one randomized trial, but every study is small, most are open-label, and all test it alongside other drugs. The evidence is suggestive for liver-related and anemia-related uses at best, and does not establish the decoction as an effective treatment for any condition.

Dosage

Study regimens only: not recommendations, and the exact recipe variant was not always specified in the trials: in an open-label study of HBsAg-positive participants (n=59) summarized in a 2023 peer-reviewed review, Phalatrikadi Kwath was administered at 40 ml twice daily for 6 months with no adverse drug reactions reported (review table, PMC10105242). In the jaundice trial, the Ghana Vati (tablet) form was given as 500 mg thrice daily after food for 15 days (IRJAY). Do not self-dose from study regimens: consult a qualified practitioner, since recipe variants differ.

Safety & contraindications

No serious adverse events were reported in the published trials: the jaundice study explicitly noted no adverse effects during the trial, and the HBsAg open-label study recorded no adverse drug reactions (IRJAY; PMC10105242). That said, trial participants were medically supervised adults (or, in the anemia trial, supervised children): supervised short-term use is not the same as proven long-term safety. There are no published safety data for use in pregnancy or breastfeeding. The Prameha-chapter variant includes Indrayana (Citrullus colocynthis, bitter apple), so variant composition matters: do not self-prepare or self-prescribe decoctions. Safety data are otherwise limited: talk to a clinician before use, especially with liver disease, diabetes, anemia, or other medications.

FAQs

What is Phalatrikadi Kwath traditionally used for?

Classical texts traditionally indicate it for prameha (urinary/metabolic disorders), pandu (anemia), kamala (jaundice), amlapitta (hyperacidity), and, in one Chakradatta verse, fever and vomiting. These are traditional indications, not clinically proven effects, and the recipe differs between the classical texts.

Is there clinical evidence it works for fatty liver?

One small randomized trial (64 patients, J-AIM 2025) tested Phalatrikadi Kwatha in fatty liver disease, but only in combination with Triphala Guggulu or Arogyavardhana Vati, with no placebo group. Both combinations eased symptoms and one improved ALT more; liver ultrasound did not change. This is suggestive, not proof that the decoction itself treats fatty liver.

Does it help anemia?

One open-label trial in 30 children with pandu (anemia) reported improved hemoglobin and symptoms after 30 days of Phalatrikadi Kwatha (J-AIM). With no control group and a small sample, the result is preliminary. It does not establish the decoction as a proven anemia treatment.

Why do different sources list different ingredients?

Because Phalatrikadi Kwath is not one fixed formula. A 2021 peer-reviewed review documents distinct versions across Charaka Samhita, Chakradatta (prameha, pandu, and amlapitta chapters), Bhavaprakasha, and Sharangadhara. Always check the ingredient list of the specific product or preparation rather than assuming a standard recipe.

What dose was used in the studies?

Study regimens are not recommendations: an open-label HBsAg study used 40 ml of the decoction twice daily for 6 months, and a jaundice trial used the tablet form at 500 mg thrice daily for 15 days. Do not self-dose from these figures; the recipe variant in each study was not always specified.

Is Phalatrikadi Kwath safe in pregnancy?

No published safety data exist for pregnancy or breastfeeding. The clinical trials enrolled supervised adults (and, in one case, supervised children): that does not establish safety in pregnancy. Avoid use in pregnancy unless a qualified practitioner advises otherwise.

Can I prepare it at home?

Not advisable without guidance. The name covers multiple classical recipes, and some variants include strong herbs such as Indrayana (Citrullus colocynthis). Misidentifying the variant or the herbs could be harmful. Any use should follow a qualified practitioner's prescription.

Sources

This article is for educational purposes only and is not medical advice. Consult a qualified practitioner before using any Ayurvedic formulation.